Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation

Lewis W. Teperman, Fred Poordad, Natalie Bzowej, Paul Martin, Surakit Pungpapong, Thomas Schiano, John Flaherty, Phillip Dinh, Stephen Rossi, G. Mani Subramanian, James Spivey

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Long-term prophylaxis with hepatitis B immunoglobulin (HBIG) for the prevention of hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) in patients with chronic HBV infection is inconvenient and costly. This randomized, prospective phase 2 study compared emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) after HBIG withdrawal to FTC/TDF plus HBIG for the prevention of HBV recurrence after OLT. Forty patients with a median time since liver transplantation of 3.4 years (interquartile range = 1.9-5.6 years) received 24 weeks of open-label FTC/TDF plus HBIG before randomization. Patients who maintained confirmed viral suppression were randomized to continue FTC/TDF plus HBIG (n = 19) or receive FTC/TDF alone (n = 18) for an additional 72 weeks. No patient experienced HBV recurrence through 72 weeks of the study while he or she was receiving the randomized treatment. Both treatment arms were safe and well tolerated; no serious or severe drug-related adverse events were observed. Renal function was consistent with that observed in a posttransplant population. The withdrawal of HBIG after 6 months' treatment with FTC/TDF should be considered in liver transplant recipients to prevent chronic HBV recurrence. Liver Transpl 19:594-601, 2013. © 2013 AASLD.

Original languageEnglish
Pages (from-to)594-601
Number of pages8
JournalLiver Transplantation
Volume19
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

Tenofovir
Hepatitis B
Liver Transplantation
Immunoglobulins
Hepatitis B virus
Recurrence
Chronic Hepatitis B
Liver
Virus Diseases
Random Allocation
Drug-Related Side Effects and Adverse Reactions
Emtricitabine
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Hepatology

Cite this

Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. / Teperman, Lewis W.; Poordad, Fred; Bzowej, Natalie; Martin, Paul; Pungpapong, Surakit; Schiano, Thomas; Flaherty, John; Dinh, Phillip; Rossi, Stephen; Subramanian, G. Mani; Spivey, James.

In: Liver Transplantation, Vol. 19, No. 6, 01.06.2013, p. 594-601.

Research output: Contribution to journalArticle

Teperman, LW, Poordad, F, Bzowej, N, Martin, P, Pungpapong, S, Schiano, T, Flaherty, J, Dinh, P, Rossi, S, Subramanian, GM & Spivey, J 2013, 'Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation', Liver Transplantation, vol. 19, no. 6, pp. 594-601. https://doi.org/10.1002/lt.23628
Teperman, Lewis W. ; Poordad, Fred ; Bzowej, Natalie ; Martin, Paul ; Pungpapong, Surakit ; Schiano, Thomas ; Flaherty, John ; Dinh, Phillip ; Rossi, Stephen ; Subramanian, G. Mani ; Spivey, James. / Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. In: Liver Transplantation. 2013 ; Vol. 19, No. 6. pp. 594-601.
@article{06258de0e98042fca1f617ed11060fda,
title = "Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation",
abstract = "Long-term prophylaxis with hepatitis B immunoglobulin (HBIG) for the prevention of hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) in patients with chronic HBV infection is inconvenient and costly. This randomized, prospective phase 2 study compared emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) after HBIG withdrawal to FTC/TDF plus HBIG for the prevention of HBV recurrence after OLT. Forty patients with a median time since liver transplantation of 3.4 years (interquartile range = 1.9-5.6 years) received 24 weeks of open-label FTC/TDF plus HBIG before randomization. Patients who maintained confirmed viral suppression were randomized to continue FTC/TDF plus HBIG (n = 19) or receive FTC/TDF alone (n = 18) for an additional 72 weeks. No patient experienced HBV recurrence through 72 weeks of the study while he or she was receiving the randomized treatment. Both treatment arms were safe and well tolerated; no serious or severe drug-related adverse events were observed. Renal function was consistent with that observed in a posttransplant population. The withdrawal of HBIG after 6 months' treatment with FTC/TDF should be considered in liver transplant recipients to prevent chronic HBV recurrence. Liver Transpl 19:594-601, 2013. {\circledC} 2013 AASLD.",
author = "Teperman, {Lewis W.} and Fred Poordad and Natalie Bzowej and Paul Martin and Surakit Pungpapong and Thomas Schiano and John Flaherty and Phillip Dinh and Stephen Rossi and Subramanian, {G. Mani} and James Spivey",
year = "2013",
month = "6",
day = "1",
doi = "10.1002/lt.23628",
language = "English",
volume = "19",
pages = "594--601",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation

AU - Teperman, Lewis W.

AU - Poordad, Fred

AU - Bzowej, Natalie

AU - Martin, Paul

AU - Pungpapong, Surakit

AU - Schiano, Thomas

AU - Flaherty, John

AU - Dinh, Phillip

AU - Rossi, Stephen

AU - Subramanian, G. Mani

AU - Spivey, James

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Long-term prophylaxis with hepatitis B immunoglobulin (HBIG) for the prevention of hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) in patients with chronic HBV infection is inconvenient and costly. This randomized, prospective phase 2 study compared emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) after HBIG withdrawal to FTC/TDF plus HBIG for the prevention of HBV recurrence after OLT. Forty patients with a median time since liver transplantation of 3.4 years (interquartile range = 1.9-5.6 years) received 24 weeks of open-label FTC/TDF plus HBIG before randomization. Patients who maintained confirmed viral suppression were randomized to continue FTC/TDF plus HBIG (n = 19) or receive FTC/TDF alone (n = 18) for an additional 72 weeks. No patient experienced HBV recurrence through 72 weeks of the study while he or she was receiving the randomized treatment. Both treatment arms were safe and well tolerated; no serious or severe drug-related adverse events were observed. Renal function was consistent with that observed in a posttransplant population. The withdrawal of HBIG after 6 months' treatment with FTC/TDF should be considered in liver transplant recipients to prevent chronic HBV recurrence. Liver Transpl 19:594-601, 2013. © 2013 AASLD.

AB - Long-term prophylaxis with hepatitis B immunoglobulin (HBIG) for the prevention of hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) in patients with chronic HBV infection is inconvenient and costly. This randomized, prospective phase 2 study compared emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) after HBIG withdrawal to FTC/TDF plus HBIG for the prevention of HBV recurrence after OLT. Forty patients with a median time since liver transplantation of 3.4 years (interquartile range = 1.9-5.6 years) received 24 weeks of open-label FTC/TDF plus HBIG before randomization. Patients who maintained confirmed viral suppression were randomized to continue FTC/TDF plus HBIG (n = 19) or receive FTC/TDF alone (n = 18) for an additional 72 weeks. No patient experienced HBV recurrence through 72 weeks of the study while he or she was receiving the randomized treatment. Both treatment arms were safe and well tolerated; no serious or severe drug-related adverse events were observed. Renal function was consistent with that observed in a posttransplant population. The withdrawal of HBIG after 6 months' treatment with FTC/TDF should be considered in liver transplant recipients to prevent chronic HBV recurrence. Liver Transpl 19:594-601, 2013. © 2013 AASLD.

UR - http://www.scopus.com/inward/record.url?scp=84878317081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878317081&partnerID=8YFLogxK

U2 - 10.1002/lt.23628

DO - 10.1002/lt.23628

M3 - Article

VL - 19

SP - 594

EP - 601

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 6

ER -